Pflug Koory’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.07M Buy
2,152
+60
+3% +$26.6K 0.43% 60
2026
Q1
$934K Sell
2,092
-11
-0.5% -$5.13K 0.43% 61
2025
Q4
$953K Sell
2,103
-34
-2% -$14.7K 0.44% 60
2025
Q3
$837K Buy
2,137
+91
+4% +$38K 0.4% 65
2025
Q2
$911K Buy
2,046
+52
+3% +$24K 0.46% 60
2025
Q1
$967K Sell
1,994
-24
-1% -$11.2K 0.54% 58
2024
Q4
$813K Buy
2,018
+79
+4% +$36.6K 0.41% 62
2024
Q3
$902K Buy
+1,939
New +$931K 0.44% 63
2024
Q1
$758K Buy
1,813
+2
+0.1% +$845 0.37% 70
2023
Q4
$737K Hold
1,811
0.39% 69
2023
Q3
$630K Sell
1,811
-10
-0.5% -$3.5K 0.36% 73
2023
Q2
$641K Sell
1,821
-30
-2% -$10.1K 0.33% 80
2023
Q1
$583K Hold
1,851
0.32% 82
2022
Q4
$535K Sell
1,851
-15
-0.8% -$4.57K 0.3% 90
2022
Q3
$540K Hold
1,866
0.33% 80
2022
Q2
$526K Hold
1,866
0.3% 86
2022
Q1
$487K Sell
1,866
-10
-0.5% -$2.37K 0.25% 93
2021
Q4
$412K Buy
1,876
+885
+89% +$172K 0.21% 105
2021
Q3
$180K Sell
991
-175
-15% -$34.2K 0.1% 166
2021
Q2
$235K Buy
1,166
+682
+141% +$143K 0.12% 152
2021
Q1
$104K Buy
+484
New +$106K 0.06% 194

Other funds holding VRTX

Pflug Koory's VRTX Position: Q2 2026 in Review

Pflug Koory increased its Vertex Pharmaceuticals (VRTX) stake by 2.9% in Q2 2026, buying an estimated $26.6K and bringing the position to 2,152 shares worth $1.07M. The position accounts for 0.43% of the portfolio, ranked #60.

Pflug Koory first reported a position in VRTX in Q1 2021 and has held it in 21 quarters since. 368 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Pflug Koory held 2,152 shares of Vertex Pharmaceuticals worth $1.07M as of Q2 2026.
  • Pflug Koory bought 60 Vertex Pharmaceuticals shares in Q2 2026, an estimated $26.6K.
  • Vertex Pharmaceuticals made up 0.43% of Pflug Koory's portfolio in Q2 2026, its #60 holding.
  • Pflug Koory first reported a position in Vertex Pharmaceuticals in Q1 2021 and has held it in 21 quarters since.
  • 368 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Pflug Koory's 13F filing for Q2 2026, filed 21 Jul 2026.